Literature DB >> 19115413

Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.

Marc Morissette1, Thérèse Di Paolo.   

Abstract

A higher prevalence and incidence of Parkinson's disease is observed in men, and beneficial motor effects of estrogens are observed in parkinsonian women. In rodents, an effect of estradiol on dopamine systems is documented, whereas much less is known in monkeys. Enkephalin was shown to exert a compensatory modulatory effect on the denervated dopamine nigrostriatal pathway in monkeys and in humans. Moreover in rodents, striatal preproenkephalin mRNA is increased by estrogen treatment. Hence, we investigated the responsiveness of striatal dopamine to estradiol in long-term ovariectomized monkeys bearing a unilateral lesion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mimic parkinsonian postmenopausal women. Seven ovariectomized female monkeys received a unilateral MPTP lesion; 4 years after ovariectomy, three received 1-month treatment with 17beta-estradiol and the others received vehicle. The lesioned striata showed extensive denervation in all monkeys as measured with dopamine and metabolite concentrations assayed by high-performance liquid chromatography and by autoradiography of the dopamine transporter. The lesioned and intact striata of estradiol-treated monkeys had increased 3-methoxytyramine, and lesioned putamen increased dopamine concentrations compared with vehicle-treated monkeys. Estradiol treatment increased the dopamine transporter in subregions of the intact caudate and putamen compared with the intact striata of vehicle-treated monkeys, but not in the lesioned striata. Preproenkephalin mRNA levels measured by in situ hybridization were increased in the lesioned striata of vehicle treated monkeys and were not further enhanced in estradiol-treated monkeys. These results show that long after ovariectomy, modeling postmenopausal hormonal conditions, brain dopamine metabolism, and transporter are still responsive to estradiol. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115413     DOI: 10.1002/jnr.21977

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

1.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 2.  The emergence of gonadal hormone influences on dopaminergic function during puberty.

Authors:  Cynthia Kuhn; Misha Johnson; Alex Thomae; Brooke Luo; Sidney A Simon; Guiying Zhou; Q David Walker
Journal:  Horm Behav       Date:  2009-11-10       Impact factor: 3.587

3.  Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Marc D Normandin; Nathaniel M Alpert; Gitte M Knudsen; Wim Vanduffel; Bruce R Rosen; Joseph B Mandeville
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-30       Impact factor: 11.205

4.  Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Authors:  Mélanie Bourque; Dean E Dluzen; Thérèse Di Paolo
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-30       Impact factor: 5.555

5.  Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

Authors:  Simon McArthur; Glenda E Gillies
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-30       Impact factor: 5.555

Review 6.  Sex differences in Parkinson's disease.

Authors:  Glenda E Gillies; Ilse S Pienaar; Shiv Vohra; Zahi Qamhawi
Journal:  Front Neuroendocrinol       Date:  2014-03-04       Impact factor: 8.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.